Essential medicines and health products

WHO publishes list of top emerging diseases likely to cause major epidemics

A panel of scientists and public health experts convened by WHO met in Geneva this week to prioritise the top ten emerging pathogens likely to cause severe outbreaks in the near future, and for which few or no medical countermeasures exist. These diseases will provide the basis for work on the WHO Blueprint for R&D preparedness to help control potential future outbreaks.

Ebola reference reagents endorsed as global standards by WHO


Ebola reference reagents produced by the National Institute for Biological Standards and Control (NIBSC) have been endorsed as the global standards for use in laboratory tests by the World Health Organisation (WHO) Expert Committee on Biological Standardisation and are now available to the scientific community.
The Ebola antibody standard will be used around the world in the testing of Ebola vaccines in development, and is expected to help accelerate the availability of new vaccines for this devastating disease.
WHO coordinated the international effort to obtain the samples that were made available for the NIBSC study. The results were then scrutinized by experts convened by WHO to see if the standards would really make a difference. There was clear evidence that they do.

New report maps progress made in Ebola R&D

Transparency and timely results sharing in clinical trials are extremely important to generate reliable evidence. They are even more crucial when testing is carried out in emergency settings.
A report published today presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.

Public consultation on ideas for potential platforms to support development and production of health technologies for priority infectious diseases with epidemic potential

The epidemic of Ebola in West Africa showed that the world is unable to develop effective interventions in a timely manner for control of severe emerging infectious diseases using current approaches to vaccine, drug and diagnostics development.

The World Health Organization (WHO) is inviting submission of structured ideas on how to improve R&D readiness for priority infectious disease threats. Specifically, propositions are requested for flexible development and production platform technologies.
Submission of platform ideas by Friday 5 February 2016, 17:00 Geneva time

fact buffet


Trials progressingPhase III vaccine trials
are progressing in Guinea
and Sierra Leone.

More about Vaccines...


Trials continueInnovative medicines,
antivirals and blood products

More about Therapies...


Four innovative Ebola diagnostics
through WHO Emergency
Use Assessment and Listing.

More about Diagnostics...

Essential Medicines and Health Products
World Health Organization